热门资讯> 正文
Arcus Biosciences获得2.5亿美元定期贷款安排
2024-08-28 04:18
- Arcus Biosciences (NYSE:RCUS) reported it has obtained a $250M term loan facility from Hercules Capital.
- The additional capital strengthens Arcus’s balance sheet and increases flexibility to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor.
- Arcus plans to present data from ARC-20, its Phase 1/1b study of casdatifan in clear cell renal cell carcinoma, later this year.
- Under the terms of the term loan facility, $50M was drawn at closing and an additional $100M is committed and fully available at Arcus’s sole option in minimum increments of $25M.
- Source: Press Release
More on Arcus Biosciences
- Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)
- Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript
- Arcus Biosciences, Inc. 2024 Q2 - Results - Earnings Call Presentation
- Arcus Biosciences GAAP EPS of -$1.02 beats by $0.11, revenue of $39M beats by $12.51M
- Gilead, Arcus combo significantly reduces death risk in colorectal cancer
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
